Sezzle Inc vs BIO-TECHNE Corp — how do they compare? Sezzle Inc trades at $118.5 (market cap $3.83B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 3× Sezzle Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sezzle Inc for 15 Days and BIO-TECHNE Corp for 63 Days on average.
| SEZL | TECH | |
|---|---|---|
Market Cap | $3.83B | $11.36B |
Volume | 341,401 | 5,390,331 |
Sector | Financials | Health |
52-Week High | $188.55 | $72.61 |
52-Week Low | $50.97 | $43.31 |
Typical Hold Time | 15 Days | 63 Days |
Enterprise Value | $3.88B | $11.39B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Sezzle (SEZL) trades at $113.85, up 0.9% with a bullish technical outlook supported by strong moving averages and ADX signals. The company demonstrates exceptional profitability with 30.35% net margins and 88.85% ROE, having beaten earnings estimates for three consecutive quarters. Recent product launches including Sezzle Send and SezzleCash are driving user growth and platform engagement.
With 67% analyst buy ratings and a $168 consensus price target suggesting 48% upside, SEZL presents growth potential despite competitive BNPL pressures. Key risks include sector volatility and execution challenges in scaling new products. The stock's current valuation at 24.97 P/E appears reasonable given its growth trajectory and profitability metrics.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Trailing returns across standard periods
Latest headlines on both assets
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →